Shilpa Gupta: Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer

Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, shared on LinkedIn:

“Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer!
A lot of progress has been made in MIBC with promising signals with ICI. (Checkmate 274, AMBASSADOR)
ctDNA appears to be a robust biomarker for patient selection. (IMvigor010)
Ongoing trial utilizing ctDNA for patient election will help advance the field further. (IMvigor011 and MODERN)
ICI not shown benefit in adjuvant UTUC, platinums remain kingpin.
Unmet need to learn from precision-oncology trials like PROOF302 (in FGFR3 select tumors).”

Source: Shilpa Gupta/LinkedIn